Checkmate Pharmaceuticals (CMPI) Short Interest Ratio & Short Volume

Short interest is the volume of Checkmate Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 78,900 shares of CMPI short. 1.23% of Checkmate Pharmaceuticals' shares are currently sold short. Learn More on Checkmate Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.23% of Checkmate Pharmaceuticals' floating shares are currently sold short.

Checkmate Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 78,900 shares, an increase of 71.5% from the previous total of 46,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Checkmate Pharmaceuticals currently has issued a total of 22,038,000 shares. Some of Checkmate Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Checkmate Pharmaceuticals currently has a public float of 6,400,000 shares.

1.23% of Checkmate Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Checkmate Pharmaceuticals: Vir Biotechnology, Inc. (11.55%), LENZ Therapeutics, Inc. (12.78%), Anavex Life Sciences Corp. (31.71%), Replimune Group, Inc. (12.57%), Immatics (6.05%), Valneva SE (0.01%), Relay Therapeutics, Inc. (11.46%), Opthea Limited (0.36%), MeiraGTx Holdings plc (3.37%), Cullinan Therapeutics, Inc. (22.53%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($3.79 billion), Palo Alto Networks, Inc. ($3.41 billion), Lucid Group, Inc. ($2.55 billion), Uber Technologies, Inc. ($2.21 billion), HP Inc. ($2.14 billion), T. Rowe Price Group, Inc. ($1.81 billion), Coinbase Global, Inc. ($1.60 billion), Take-Two Interactive Software, Inc. ($1.58 billion), Lumen Technologies, Inc. ($1.56 billion), and Rivian Automotive, Inc. ($1.55 billion). View all of the most shorted stocks.

Short selling CMPI is an investing strategy that aims to generate trading profit from Checkmate Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Checkmate Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CMPI, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CMPI, twice per month. The most recent reporting period available is May, 15 2022.